Lars Erik Krag

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Per Eystein Lønning, Jürgen Geisler, Lars Erik Krag et al. · Journal of Clinical Oncology · 2005 · 293 citations · Full text

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study

Jürgen Geisler, Per Eystein Lønning, Lars Erik Krag et al. · European Journal of Cancer · 2006 · 100 citations

Breast Oncology, Lipid Metabolism, Early Breast Cancer +10

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk

Jürgen Geisler, Lars Erik Krag, Lars Ottestad et al. · Journal of Clinical Oncology · 2004 · 26 citations

E 25, Breast Oncology, Pharmacotherapy +22

Vitamin D deficiency: A threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors

Jürgen Geisler, Lars Erik Krag, Erik Løkkevik et al. · Journal of Clinical Oncology · 2006 · 15 citations

Breast Oncology, Pharmacotherapy, Orthopaedic Surgery +21

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study

Jürgen Geisler, Lars Erik Krag, Lars Ottestad et al. · Journal of Clinical Oncology · 2004 · 14 citations